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Background: Cyclooxygenases (COX) play a key role in prostaglandin metabolism and are important for tumor
development and progression. The aim of this study was to analyze the prognostic impact of COX-2 expression in a
cohort of lymph node-negative breast cancer patients not treated in the adjuvant setting.
Methods: COX-2 expression was determined by immunohistochemistry (IHC) in tumor tissue of 193 node-negative
breast cancer patients. Additionally, mRNA expression was determined in corresponding tumor samples using
microarray based gene-expression data. Univariate and multivariate Cox regression analyses adjusted for age at
diagnosis, tumor size, histological grade, human epithelial growth factor receptor 2 (HER2), estrogen receptor (ER)
and progesterone receptor (PR) were performed to evaluate the association of both COX-2 protein and mRNA
expression with survival. Survival rates were determined by the Kaplan-Meier method. Correlations between
COX-2 expression and established prognostic factors were analyzed using the Chi-square test. A potential correlation
between COX-2 protein expression and COX-2 mRNA expression was assessed utilizing the Kruscal-Wallis-H-test.
Results: COX-2 protein expression was positive in 24.9% of the breast cancer samples. Univariate analysis showed that
COX-2 protein expression was associated with shorter disease-free survival (DFS) (P = 0.0001), metastasis-free survival
(MFS) (P = 0.002) as well as breast cancer specific overall survival (OS) (P = 0.043). In multivariate analysis COX-2 expression
retained its significance independent of established prognostic factors for shorter DFS (P < 0.001, HR = 2.767,
95% CI = 1.563-4.901) and for inferior MFS (P = 0.002, HR = 2.7, 95% CI = 1.469-5.263) but not for OS (P = 0.096,
HR = 1.929, 95% CI = 0.889-4.187). In contrast, COX-2 mRNA expression was not related to survival and failed to
show a correlation with protein expression (P = 0.410).
Conclusions: The present findings support the hypothesis that COX-2 protein but not mRNA expression is associated
with an unfavorable outcome in node-negative breast cancer.
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It is increasingly recognized that the immune system has
a large influence on tumorigenesis. Inflammation is able
to promote cancer initiation and progression. The causal
relationship between chronic inflammation within the
local tissue environment and cancer has been in the
focus of research in recent years, leading to the concept of* Correspondence: marcus.schmidt@unimedizin-mainz.de
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unless otherwise stated.cancer-related inflammation as an emerging hallmark
of cancer [1]. Cyclooxygenases regulate the synthesis of
prostaglandins and play a substantial role in inflammation.
There are two isoforms: Cyclooxygenase-1 is expressed in a
constitutive manner whereas Cyclooxygenase-2 (COX-2) is
induced by growth factors as well as inflammation and is
involved in tumor development and progression [2].
COX-2 selective inhibitors reduce tumorigenesis in rat
models and the role of Cox-2 as a target of selective
Cox-2 inhibitors in treatment and prevention carcinoma
is discussed [3]. In a recent large metaanalysis of patientsLtd. This is an Open Access article distributed under the terms of the Creative
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including COX-2 selective COXibs, NSAID use was asso-
ciated with reduced risk for breast cancer (relative risk
[RR] = 0.88, 95% confidence interval [95% CI] = 0.84 to
0.93) [4]. However, other studies failed to confirm a
protective impact of NSAID on breast cancer incidence
regardless of the molecular subtype [5]. Considering
treatment with selective COX-2 inhibitors, celecoxib
resulted in a pre-operative randomized phase II trial in
an anti-tumor transcriptional response in primary breast
cancer with a substantial decrease in Ki-67 positive cells
as compared to placebo [6]. Conversely, the addition of
celecoxib to exemestane failed to show an increased bene-
fit in a randomized phase II trial as compared to exemes-
tane alone in metastatic breast cancer [7]. Regarding the
prognostic role of Cox-2 expression, results are similarly
divided. Some of these biomarker studies described an
unfavourable prognostic role of COX-2 in early breast
cancer [8-11]. However, other studies failed to show an
association of COX-2 and prognosis [12-14]. The vast
majority of these studies used immunohistochemistry to
examine the expression of COX-2 on the protein level. In-
vestigations analyzing mRNA expression of COX-2 rarely
considered an association with prognosis [15,16]. Further-
more, the studies mentioned above used cohorts of breast
cancer patients treated with different adjuvant systemic
therapies. Because of this it is hardly possible to clarify
whether the impact of COX-2 overexpression is purely
prognostic in nature or confounded by predictive effects.
Therefore, the aim of the present study was to examine
COX-2 expression on the protein as well as on the mRNA
level in an untreated cohort of lymph node-negative breast




The initial study cohort consisted of 410 consecutive
lymph node-negative breast cancer patients. Of these
410 patients, tumor tissue for Cox-2 immunohistochem-
istry as well as for mRNA analysis was available in 193
patients. Patients were treated at the Department of Ob-
stetrics and Gynecology, Johannes Gutenberg University
Mainz between the years 1986-1999. Adequate follow-up
information of all patients was available. All patients were
treated by surgical tumor resection, either modified radical
mastectomy (n = 70, 36.3%) or breast conserving surgery
followed by irradiation (n = 123, 63.7%), and did not re-
ceive any systemic therapy in the adjuvant setting. pT
stage was collected from the pathology report of the
Gynecological Pathology Division. From the breast cancer
database [17], information on age at diagnosis, histological
grade, estrogen receptor (ER), progesterone receptor (PR)
and human epidermal growth factor receptor 2 (HER2)status were obtained (Table 1). The median follow-up time
was 11.2 years. We documented death from cancer or un-
related to breast cancer and recurrence of disease, which
include metastasis and local relapse. 31 (16%) patients
died from breast cancer, 25 (13.8%) patients died from
causes unrelated to breast cancer, and 138 (70.1%) patients
were alive at the date of last follow-up, 21 (10.8%) patients
suffered from locally-recurrent disease and 45 (23.2%) de-
veloped distant metastasis. 5 (2.6%) patients developed
contralateral breast cancer. The current study was con-
ducted according to the reporting recommendations for
tumor marker prognostic studies (REMARK) [18].Immunohistochemistry
Immunostaining was done on 4 μm thick sections ac-
cording to standard procedures. Briefly, serial sections
of formalin-fixed and paraffin-embedded tumour tissue
were subsequently deparaffinized using graded alcohol
and xylene. Antigen retrieval reactions were performed
in a steamer in citrate buffer of pH10 for 30 minutes.
3% H2O2 solution was applied to block endogenous
peroxidase at room temperature for 5 minutes. Mono-
clonal COX-2 antibody (Clone SP21; DCS, Hamburg,
Germany) in a dilution of 1:100 was used to incubate with
the tissue sections for 30 minutes at room temperature in
a humidified chamber, followed by polymeric biotin–free
visualization system (Envision™, DAKO Diagnostic Com-
pany, Hamburg, Germany) reaction for 30 minutes at
room temperature. Then the sections were incubated with
3,3-diaminobenzidine (DAB) in a dilution of 1:50 with
substrate buffer for 5 minutes at room temperature and
counterstained with Mayer’s haematoxylin solution for 5
minutes. All slides were mounted and then were evaluated
under a Leica light microscope (Leica Microsystem Vertrieb
Company, Wetzler, Germany) by two of the authors trained
in histological and immunohistochemical diagnostics,
unaware of the clinical outcome. All series included ap-
propriate positive and negative controls, and all controls
gave adequate results.Evaluation of COX-2 immunostaining
Since evaluation of COX-2 expression is not yet stan-
dardized, the following scoring criteria were applied:
(i) intensity score (IS): intensity of staining was scored
as 0 (negative), 1 (weak), 2 (moderate), or 3 (strong),
(ii) proportion score (PS) percentage of positive cells
was scored as 0 (0% positive cells), 1 (1-10% positive
cells), 2 (11-50% positive cells), 3 (51-80% positive
cells), or 4 (>80% positive cells). To separate tumors
with positive COX-2 expression from tumors with
negative COX-2 expression, we regarded the COX-2
immunostaining status as positive when staining inten-
sity was scored 3 and as negative in all other cases.
Table 1 Clinicopathological characteristics of node
negative breast cancer patients from the Mainz cohort
with available gene array and COX-2 immunostaining
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Table 1 Clinicopathological characteristics of node
negative breast cancer patients from the Mainz cohort
with available gene array and COX-2 immunostaining
data (n = 193) (Continued)
4 59 30.6













1The hormone receptor status is positive as soon as one of both, the estrogen
or the progesterone receptor status, is positive.
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as COX-2 immunostaining score, ranging from 0-12.
Gene array data for fresh frozen tissue
Three previously published datasets for untreated node-
negative breast cancer patients were used. The large com-
bined group of 788 patients included the Mainz cohort
with 200 patients (GSE11121.), 193 of these with corre-
sponding COX-2 IHC [19], the Rotterdam cohort with
286 patients (GSE2034) [20], and the TRANSBIG cohort
with 302 patients (GSE6532, GSE7390) [21,22]. These co-
horts comprise available microarray datasets for medically
untreated node-negative breast cancer which have used
metastasis-free survival (MFS) as an end point.
Gene expression profiling and data processing
For the Mainz, Rotterdam, and TRANSBIG cohorts, the
Affymetrix, Inc. (Santa Clara, California) Human Genome
U133A Array set and GeneChip SystemTM were used to
quantify the relative transcript abundance in the breast
cancer tissues, as previously described [19], and the ro-
bust multiarray average (RMA) algorithm was used for
normalization. To analyze COX-2 mRNA expression
from the gene array data, probe set 204748_at was used
in all cohorts. This probe set has been validated in a
previous publication, where the influence of estradiol
expression on COX-2 RNA levels has been studied [23].
COX-2 expression was additionally analyzed by qRT-PCR
using the following primers: forward: 5′-ATCATAAGC
AGGGCCAGCT-3′, reverse: 5′-AAGGCGCAGTTTACG
CTGTC-3′, resulting in a 101 bp fragment. Similar results
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using the above mentioned primers.
Ethics Statement
The study was approved by the ethical review board of
the medical association of Rhineland-Palatinate, Germany.
Informed consent has been obtained and all clinical inves-
tigation has been conducted according to the principles
expressed in the Declaration of Helsinki.
Statistical analysis
Univariate and multivariate Cox regression analyses were
performed with inclusion to evaluate the association be-
tween COX-2 expression in breast carcinoma samples and
established prognostic factors such as age at diagnosis,
tumor size, histological grade of differentiation, HER2 sta-
tus, ER and PR with survival time. Dichotomization was
done as follows: COX-2 immunostaining status in positive
versus negative, age at diagnosis in ≤50 years versus > 50
years, tumor size in pT1 (≤2cm) versus pT2 and pT3
(>2 cm), histological grade of differentiation in G I and II
versus G III, HER2 status in positive versus negative and
ER status in positive (IRS 1-12) versus negative (IRS 0).
Survival rates were determined by the Kaplan-Meier
method and survival times were compared using the
Log-rank test. Breast cancer-specific disease-free sur-
vival (DFS) was specified the time between the date of
surgery and the date of loco-regional or metastatic re-
currence, breast cancer related death or last follow-up.
Metastasis-free survival (MFS) was defined as the time
between date of surgery and diagnosis of distant me-
tastasis. Breast cancer specific overall survival (OS)
was defined as the time between the date of surgery
and the date of death. Patients who died of an un-
known or unrelated cause were censored at the date of
death. Correlations between COX-2 immunostaining
status, age at diagnosis, tumor size, histological grade
of differentiation, hormone receptor status, HER2 status,
ER and PR were assessed using the Chi-square test. A po-
tential correlation between COX-2 protein expression and
COX-2 mRNA expression was assessed using the Kruscal-
Wallis-H-test (two-sided test). All P values are two sided.
Since no correction for multiple testing was performed,
all results must be interpreted as explorative. Statistical
analyses were performed using the Statistical Package
for Social Science (SPSS) (SPSS Inc, version 20, Chicago,
IL, USA).
Results
Immunohistochemically determined COX-2 expression
independently predicts prognosis
To analyze whether COX-2 immunostaining data are
associated with prognosis we stained paraffin slices of a
cohort of node negative breast carcinomas that recentlyhave been used in Affymetrix RNA profiling studies
(Mainz cohort) [19]. Results of immunostaining were
assessed using an intensity score (IS: 0-3) and a proportion
score (PS: 0-4). Intensity scores of 0-3 were observed for
18.1, 23.2, 33.7 and 24.9% of the patients, respectively
(Table 1). Proportion scores of 0-4 were obtained for 18.1,
12.4, 21.8, 17.1 and 30.6%, respectively. Representative pic-
tures of COX-2 immunostaining illustrate that the most
striking difference was seen between tumors with the
highest possible intensity score of three versus smaller
than three (Figure 1). Therefore, we first analyzed DFS
in relation to the COX-2 immunostaining status (IS = 3
versus IS < 3). Prognosis of patients with IS = 3 was sig-
nificantly worse compared to patients with IS < 3 in the
univariate (P = 0.001; HR = 2.4) and in the multivariate
(P < 0.001; HR = 2.8) Cox analysis, adjusted for age,
pTstage, grading, hormone and HER2 status (Table 2).
Importantly, the association between COX-2 immuno-
staining and disease-free survival did not depend on a
specific mode of dichotomization of the patients into
two groups but all previously reported strategies of
immunostaining interpretation resulted in significant
results: (i) Intensity and proportion scores were multiplied
resulting in an “immunostaining score” (0-12) which was
significantly associated with DFS in the multivariate Cox
model (P = 0.020; HR = 1.1, Additional file 1: Table S1). (ii)
It has been reported that for some prognostic factors only
the highest immunostaining score is relevant with respect
to prognosis. Therefore, we compared patients with im-
munostaining scores =12 versus <12 which also led to a
significant association with DFS (P = 0.013, HR = 2.4,
Additional file 1: Table S2). (iii) Her2 is interpreted as
“status positive” when an intensity score of 3 is observed
in more than 10% of all tumour cells [24]. Also a “COX-
2 status” derived by this rule was significantly associated
with DFS (P < 0.001, HR = 3.2, Additional file 1:
Table S3). However, it should be considered that “COX-
2 status positive” differed from “intensity score = 3” (see
above) in only 5 patients which did not have a relevant
influence on the result of the Cox analysis. In conclusion,
we observed a robust association between immunohisto-
chemically determined COX-2 protein expression and DFS
and, hence, used COX-2 immunostaining status as defined
by IS = 3 for further analyses.
COX-2 and metastasis-free survival
DFS includes the events (i) regional recurrence of breast
cancer, (ii) distant metastasis and (iii) contra lateral breast
cancer. In a next step we focussed on a possible relation-
ship between COX-2 expression and distant metastasis.
Immunohistochemically determined COX-2 was also sig-
nificantly associated with MFS in the univariate (P = 0.002;
HR = 2.6) and multivariate (P = 0.002, HR = 2.7) Cox ana-
lysis as shown for the COX-2 intensity score (IS = 3 versus
Figure 1 Representative examples of COX-2 immunohistochemistry in breast carcinoma specimens, A: Staining Intensity (SI) score 0
(absent), B: SI score 1 (weak), C: SI score 2 (moderate), D: SI score 3 (strong); (original magnification: 400-fold).
Table 2 Association of COX-2 immunostaining status
(intensity 3 vs 0-2) with breast cancer specific disease-free
survival (DFS) in the Mainz cohort of node negative
breast cancer patients (n = 193)
A. Univariate Cox analysis
Prognostic factor p HR 95% CI
COX-2 immunostaining status 0.001 2.427 1.426-4.131
B. Multivariate Cox analysis
Prognostic factors p HR 95% CI
Age 0.467 0.802 0.443-1.452
(<50 vs ≥50 years)
pT stage 0.815 1.068 0.614-1.861
(≤2cm vs >2cm)
Histological grade
(Grade 3 vs grade 1 and 2) <0.001 4.510 2.562-7.940
HR1 (ER or PR) 0.523 0.813 0.431-1534
(negative vs. positive)
HER-2 status 0.498 1.273 0.633-2.559
(positive vs negative)
COX-2 immunostaining status <0.001 2.767 1.563-4.901
1The hormone receptor status (HR) is positive as soon as one of both, the
estrogen (ER) or the progesterone receptor status (PR), is positive.
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vival (OS) showed only a trend in the multivariate analysis
(univariate: P = 0.043, HR = 2.1; multivariate: P = 0.096;
HR = 1.929) (Table 4). The worse association for overall
survival is not surprising, since (i) the number of death
events is smaller compared to relapse events (Table 1) and
(ii) several further factors like differences in the treatment
of relapsed disease may influence the length of the time
period between relapse and death.
In a next step DFS and MFS time as well as OS time
were visualized by Kaplan-Meier plots. Obviously, the
major difference was observed between intensity score 3
and lower scores (Figure 1). Therefore, the dichotomization
using the COX-2 immunostaining status (IS = 3 vs <3)
seems to be reasonable. In contrast to COX-2 immuno-
staining status (Figure 2) the COX-2 proportion score
(reflecting the fraction of COX-2 positive tumour cells in-
dependent from their staining intensity) was not associ-
ated with prognosis in Kaplan-Meier analysis (data not
shown). This illustrates that identification of patients with
high staining intensity is the most critical requirement for
immunostaining of COX-2.
COX-2 mRNA expression does not correlate with protein
levels and is not associated with prognosis
The same tumours from the Mainz cohort that have
been studied by immunostaining were analyzed for
COX-2 mRNA expression using Affymetrix microarrays
Table 3 Association of COX-2 immunostaining status
(intensity score 3 vs 0-2) with breast cancer specific
metastasis-free survival (MFS) in the Mainz cohort of
node negative breast cancer patients (n = 193)
A. Univariate Cox analysis
Prognostic factor p HR 95% CI
COX-2 intensity score 0.002 2.582 1.418-4.703
B. Multivariate Cox analysis
Prognostic factors p HR 95% CI
Age 0.693 0.869 0.432-1.747
(<50 vs ≥50 years)
pT stage 0.287 1.411 0.749-2.658
(≤2cm vs >2cm)
Histological grade
(Grade 3 vs grade 1 and 2) <0.001 4.315 2.275-8.182
HR1 (ER or PR) 0.888 0.951 0.471-1.920
(negative vs. positive)
HER-2 status 0.122 1.798 0.855-3.783
(positive vs negative)
COX-2 intensity score 0.002 2.70 1.469-5.263
1The hormone receptor status (HR) is positive as soon as one of both, the
estrogen (ER) or the progesterone receptor status (PR), is positive.
Table 4 Association of COX-2 immunostaining status
(intensity 3 vs 0-2) with breast cancer specific overall
survival (OS) in the Mainz cohort of node negative
breast cancer patients (n = 193)
A. Univariate Cox analysis
Prognostic factor p HR 95% CI
COX-2 immunostaining status 0.043 2.128 1.023-4.427
B. Multivariate Cox analysis
Prognostic factors p HR 95% CI
Age 0.984 0.991 0.418-2.350
(<50 vs ≥50 years)
pT stage 0.547 1.262 0.592-2.693
(≤2cm vs >2cm)
Histological grade
(Grade 3 vs grade 1 and 2) <0.001 5.331 2.325-12.223
HR1 (ER or PR) 0.812 0.903 0.391-2.089
(Negative vs. positive)
HER-2 status 0.290 1.592 0.672-3.770
(Positive vs negative)
COX-2 immunostaining status 0.096 1.929 0.889-4.187
1The hormone receptor status (HR) is positive as soon as one of both, the
estrogen (ER) or the progesterone receptor status (PR), is positive.
Figure 2 Positive COX-2 immunostaining status is associated
with shorter disease free survival time (A), shorter metastasis
free survival time (B) and shorter overall survival (C) time in
node-negative breast cancer patients.
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tion score correlated with COX-2 mRNA expression
(Figure 3). COX-2 mRNA expression was not associated
with DFS, MFS and OS, neither in the univariate nor in
the multivariate Cox model (Additional file 1: Tables
S4-S6). To analyze whether the lack of association be-
tween COX-2 mRNA expression and prognosis may be
due to a too low case number in our cohort (n = 193),
Figure 3 Correlation of COX-2 mRNA with COX-2 intensity score
(A) and COX-2 immunostaining score (B).
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cohorts of node-negative breast cancer patients into this
study, namely the Rotterdam (n = 286) and the TRANS-
BIG (n = 302) cohorts. In none of these cohorts was high
COX-2 RNA expression associated with worse prognosis.
Even if we combined all three cohorts leading to a large
group of 788 patients with node-negative breast cancer,
no association between COX-2 mRNA expression and
metastasis free survival was obtained (Additional file 1:
Table S7).
Correlation of COX-2 protein expression with other
established prognostic factors
Furthermore, we investigated correlations of the COX-2
immunostaining status with well-established prognostic
factors. COX-2 protein expression failed to show an as-
sociation with age at diagnosis (P = 0.708) (Additional
file 1: Table S8A), tumor size (P = 0.508) (Additional file 1:
Table S8B), histologic grading (P = 0.904) (Additional
file 1: Table S8C), hormone receptor status (P = 0.125)(Additional file 1: Table S8D), PR (P = 0.773) (Additional
file 1: Table S8E) or HER2 status (P = 0.453) (Additional
file 1: Table S8F). Only ER showed an association with
COX-2 protein expression (P = 0.041) (Additional file 1:
Table S8G). ER positive carcinomas were more likely to
show COX-2 protein expression.
Discussion
Prognostic markers are needed to define node-negative
high-risk patients who would benefit from additional
adjuvant systemic treatment. To the best of our knowledge
the current study is the first to examine the prognostic im-
pact of COX-2 expression in patients with node-negative
breast carcinoma, who received no systemic treatment in
the adjuvant setting. This cohort allows the assessment of
the pure prognostic effect of COX-2 without any confound-
ing predictive effects. In our study, increased protein ex-
pression of COX-2 using a COX-2 immunostaining status
(IS = 3) was detected in 22.3% of the breast carcinoma
samples. Positive COX-2 protein expression was associ-
ated with shorter DFS, MFS, and OS in univariate analysis.
COX-2 expression was also correlated to DFS and MFS
independent of other established prognostic factors. For
OS, this correlation showed only a trend. The worse asso-
ciation for overall survival in our study is not surprising,
since the number of death events is smaller compared to
relapse events and several further factors may influence
the length of the time period between relapse and death.
The expression of COX-2 in breast cancer has been
observed in several studies. COX-2 protein expression
varies from 17.4% [25] to 57.3% [26]. This diversity of
COX-2 positivity in breast cancer may be due to differ-
ent analytical methods, cut-off values and patient char-
acteristics. In the present study we defined a COX-2
positive status only when staining intensity was scored
3, explaining why the detection rate was comparably
low with 22.3%. This is similar to Kim and co-workers
who regarded a staining intensity of 2 and 3 as positive
[27]. In their study of postmastectomy chest wall relapse,
COX-2 protein expression correlated with increased dis-
tant metastasis [27]. In line with their findings, several
other retrospective studies have reported that increased
protein expression of COX-2 is a negative prognostic
marker for increased metastasis or reduced overall sur-
vival in primary breast cancer [9,8,10,11]. However, the as-
sociation of COX-2 and survival remains controversial
[28-31]. For instance, Holmes and co-workers reported re-
cently that the higher risk of breast cancer death among
women with COX-2 positive tumors was fully accounted
for by worse stage at diagnosis [28]. However, since the
aforementioned studies are retrospective and differ in
composition of the examined cohorts of patients as well
as in the study design, we felt that further studies in a
more homogeneous cohort of breast cancer patients were
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prognosis.
The association of COX-2 with established prognos-
tic factors is similarly controversial. Contrary to several
studies relating COX-2 expression to parameters that
characterized the aggressiveness of breast cancer, such
as large tumor size, axillary lymph node metastasis,
high histologic grading, negative hormone receptor
status and positive Her-2 status, [9,11,10,30,8] our
results indicate that COX-2 protein expression has a
positive correlation with ER.
The strength of the present study is that we included
only patients with node-negative breast cancer not
treated in the adjuvant setting, suggesting that in early
breast cancer COX-2 expression is indeed independent
of other prognostic factors. Moreover, the same tumor
tissue specimens analyzed by immunohistochemistry in
the present study have also been analyzed by Affymetrix
gene arrays. We found that COX-2 mRNA expression
does not correlate with protein expression and that,
contrary to COX-2 protein expression, mRNA expression
is not related to outcome. Boneberg and co-workers com-
pared expression profiles of COX-2 in 48 breast cancer
tissues, 41 tumor-adjacent tissues, and 12 breast tissue
samples utilizing RT-PCR [32]. Surprisingly, the expres-
sion of COX-2 mRNA was decreased in the breast cancer
samples not overexpressed as previously reported using
immunohistochemistry. A potential association with sur-
vival was not examined in their study. Similarly, the study
of McCarthy also used real-time RT-PCR in small cohort
of breast cancer samples (n = 45) without looking at the
prognostic impact of COX-2 mRNA expression [16]. In
contrast to our negative results with COX-2 mRNA levels
we found a highly significant association between COX-2
immunohistochemistry and outcome in the same cohort
of node-negative breast cancer patients. The most likely
explanation for these seemingly discrepant results is
that COX-2 protein levels in breast cancer tissue pre-
dominantly depend on translation and protein stability.
Therefore, COX-2 protein measured with immunohisto-
chemistry seems to be more relevant for prognosis than
COX-2 mRNA levels.
Conclusions
In conclusion, our results provide further evidence that
increased COX-2 protein expression is associated with
poor disease-free survival and metastasis-free survival
independent of other prognostic factors. In this context
it is tempting to speculate that treatment with a selective
COX-2 inhibitor might improve the poor prognosis of
patients with overexpression of COX-2. Even though our
study presents a well-characterized and homogenous
cohort of node-negative breast cancer patients not
treated in the adjuvant setting, which takes both potentialpredictive effects as well as a relationship of COX-2 with
increased stage of disease out of the equation, it suffers
from the usual limitations of a retrospective study design.
Because of this, the proposed prognostic impact of COX-2
expression in early breast cancer has to be interpreted
with caution. Prospective studies will be necessary to
evaluate the prognostic effect of COX-2 protein expres-
sion in breast cancer patients.
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